Patents Represented by Attorney, Agent or Law Firm David A. Lowin
-
Patent number: 5380879Abstract: The disclosed derivatives of mycophenolic acid are therapeutic agents advantageous in the treatment of disease states indicated for mycophenolic acid and/or mycophenolate mofetil and other immunosuppressant agents.Type: GrantFiled: February 18, 1994Date of Patent: January 10, 1995Assignee: Syntex (U.S.A.) Inc.Inventor: Eric B. Sjogren
-
Patent number: 5378847Abstract: The invention provides a new and efficient process for preparing 2,4(5)-substituted or 1,2,4-substituted imidazole derivatives.The invention also provides a process for preparing substituted aminoalkylimidazole derivatives, useful for the treatment of mammals having a variety of disease states, including stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and the like.Type: GrantFiled: December 21, 1993Date of Patent: January 3, 1995Assignee: Syntex Pharmaceuticals, Ltd.Inventors: Gary McCort, Jean-Claude Pascal
-
Patent number: 5366737Abstract: This invention relates to compounds of the formulaor an optical isomer thereof wherein R.sup.1 and R.sup.2 are the same or different and are an alkyl or alkenyl group of 6 to 24 carbon atoms; R.sup.3, R.sup.4 and R.sup.5 are the same or different and are alkyl of 1 to 8 carbon atoms, aryl, aralkyl of 7 to 11 carbon atoms, or when two or three of R.sup.3, R.sup.4, and R.sup.5 are taken together to form quinuclidino, piperidino, pyrrolidino, or morpholino; n is 1 to 8; and X is a pharmaceutically acceptable anion.Type: GrantFiled: February 10, 1993Date of Patent: November 22, 1994Assignee: Syntex (U.S.A.) Inc.Inventors: Deborah A. Eppstein, Philip L. Felgner, Thomas R. Gadek, Gordon H. Jones, Richard B. Roman
-
Patent number: 5342953Abstract: Compounds of the formula: ##STR1## wherein: A is oxo or dioxo;R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen or lower alkyl of one to six carbon atoms;R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are independently hydrogen, lower alkyl of one to six carbon atoms, alkoxy, acyl or halo;are advantageously converted to thieno[3,2-c]pyridine derivatives and the pharmaceutically acceptable salts thereof, particularly ticlopidine hydrochloride.Type: GrantFiled: January 31, 1991Date of Patent: August 30, 1994Assignee: Syntex (U.S.A.) Inc.Inventors: Gary F. Cooper, Keith E. McCarthy
-
Patent number: 5296609Abstract: The invention provides a new and efficient process for preparing 2,4(5)-substituted or 1,2,4-substituted imidazole derivatives.The invention also provides a process for preparing substituted aminoalkylimidazole derivatives, useful for the treatment of mammals having a variety of disease states, including stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism, and the like.The invention also relates to novel aminoalkylimidazole compounds.Type: GrantFiled: April 9, 1993Date of Patent: March 22, 1994Assignee: Syntex Pharmaceuticals, Ltd.Inventors: Gary McCort, Jean-Claude Pascal
-
Patent number: 5284971Abstract: Compounds of general formula (I) ##STR1## wherein R.sup.1 is (CH.sub.2).sub.n ((CHNR.sup.7 R.sup.8).sub.m C(O)R.sup.9 ; n=1-3; and m=0 or 1;R.sup.3 and R.sup.5 are independently Cl, Br, I, or CH.sub.3 ;R.sup.7 and R.sup.8 are independently H or (C.sub.1 -C.sub.4)alkyl;R.sup.9 is OH, (C.sub.1 -C.sub.4)alkoxy, or NR.sup.7 R.sup.8 ;R.sup.31 is H, Cl, Br, I, (C.sub.1 -C.sub.4)alkyl, (C.sub.4 -C.sub.6)cycloalkyl, (C.sub.1 -C.sub.4)haloalkyl, (C.sub.4 -C.sub.6)halocycloalkyl, or --CH(R.sup.10)Ar where Ar is selected from 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, and 6-methoxypyridazin-3-yl N-oxide and R.sup.10 is H or (C.sub.1 -C.sub.4)alkyl;R.sup.41 is OH or a bioprecursor thereof; and the pharmaceutically acceptable salts thereof; are structural analogs of the thyroid hormones T.sub.3 and T.sub.4 and exhibit selective thyromimetic activity.Type: GrantFiled: July 16, 1992Date of Patent: February 8, 1994Assignee: Syntex (U.S.A.) Inc.Inventors: Keith A. Walker, Sharada S. Labadie, Denis J. Kertesz, Craig W. Laughton
-
Patent number: 5276034Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives and the pharmaceutically acceptable salts thereof are useful for treating mammals having any of a variety of disease states. These disease states include: 1) diseases treated by direct neuronal protection, including focal and global ischemia, spinal injuries, and head trauma, and neurological diseases including Alzheimer's and Huntington's chorea; 2) uraemic and hyponatraemic encephalopathy; 3) diseases treated by diuresis; 4) diseases treated by calcium channel antagonism, including cardiovascular diseases (i.e. hypertension, angina, stable and unstable angina, Prinzmetal angina, arrhythmia, thrombosis, embolism, and congestive heart failure including chronic or acute cardiac failure), diseases characterized by ischemia of lower legs due to peripheral vascular disease (e.g., intermittent claudication), diseases characterized by spasms of smooth muscle (i.e.Type: GrantFiled: April 19, 1991Date of Patent: January 4, 1994Assignee: Syntex Pharmaceutical Ltd.Inventors: Jean C. Pascal, Chi-Ho Lee, Brian J. Alps, Henri Pinhas, Roger L. Whiting, Calum B. MacFarlane, Serge Beranger, Robert J. Dow
-
Patent number: 5272063Abstract: A method for the construction of recombinant DNA molecules capable of producing biologically active human nerve growth factor (hNGF) in insect cells is disclosed. Expression of the mature protein is achieved using the baculovirus expression system. The biologically active hNGF so produced is potentially of value in the treatment of patients suffering from Alzheimer's Disease and other neurological disorders.Type: GrantFiled: July 20, 1989Date of Patent: December 21, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Hardy W. Chan, Jim W. Barnett, Preston A. Baecker, Hela Bursztyn-Pettegrew, Binh T. Nguyen, Carol Ward
-
Patent number: 5264437Abstract: The present invention relates to optionally substituted pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones or optionally substituted pyrido[2,3-d]pyrimidine-2(1H,3H)-ones, i.e., compounds of Formula I: ##STR1## wherein: Y is --CH.sub.2 -- or --C(O)--;R.sup.1 is hydrogen or --(CH.sub.2).sub.n --R.sup.7, wherein:R.sup.7 is aryl or heteroaryl, andn is 1 or 2,provided that when Y is --C(O)--, R.sup.7 is heteroaryl; andR.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are hydrogen, or one is selected from lower alkyl, halo, carboxy, methoxycarbonyl, carbamoyl, methylcarbamoyl, di-methylcarbamoyl, methylcarbonyl, methylthio, methylsulfinyl, methylsulfonyl, hydroxymethyl, amino, trifluoromethyl, cyano or nitro; orR.sup.2, R.sup.3, R.sup.4 and R.sup.5 are independently selected from hydrogen, lower alkyl, nitro, chloro, fluoro, methoxycarbonyl or methylcarbonyl, provided at least one is hydrogen, and R.sup.6 is hydrogen;or a pharmaceutically acceptable ester, ether or salt thereof.Type: GrantFiled: March 20, 1992Date of Patent: November 23, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Robert S. Wilhelm, Ronnie L. Chin, Bruce H. Devens, Robert Alvarez
-
Patent number: 5252736Abstract: Substituted imidazolyl-alkyl-piperazine and diazepine derivatives of Formula A: ##STR1## wherein: R.sup.1 is aryl, lower alkyl, cycloalkyl or hydrogen;R.sup.2 is aryl, lower alkyl or hydrogen;R.sup.3 is lower alkyl, hydroxy, or hydrogen;R.sup.4 is aryl or hydrogen;R.sup.5 is aryl or hydrogen;m is two or three;n is zero, one or two, provided that when R.sup.3 is hydroxy, n is oneor two; andq is zero, one, two, or three;and the pharmaceutically acceptable salts thereof, are calcium channel antagonists useful for treating mammals having a variety of disease states, such as stroke, epilepsy, hypertension, angina, migraine, arrhythmia, thrombosis, embolism and also for treatment of spinal injuries.Type: GrantFiled: November 7, 1991Date of Patent: October 12, 1993Assignee: Syntex Pharmaceuticals, Ltd.Inventors: Jean C. Pascal, Chi-Ho Lee, Brian J. Alps, Henri Pinhas, Roger L. Whiting
-
Patent number: 5250547Abstract: Compounds of the Formula: ##STR1## wherein: R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl, or when taken together with the carbon to which they are attached are cycloalkyl of 3 to 8 carbon atoms;R.sup.3 is fluoro lower alkyl; cyano; or nitro;R.sup.4 is ##STR2## R.sup.5 and R.sup.6 are independently hydrogen or lower alkyl; and R.sup.7 is --NR.sup.8 R.sup.9 ; wherein:R.sup.8 is hydrogen; lower alkyl; lower alkoxy; hydroxy; or hydroxy lower alkyl; andR.sup.9 is hydrogen; lower alkyl; hydroxy lower alkyl; --SO.sub.2 R.sup.10 ; --CO.sub.2 R.sup.10 ; --C(O)NR.sup.11 R.sup.12 ; --C(S)NR.sup.11 R.sup.12 ; or --C(O)R.sup.12 ;whereinR.sup.10 is lower alkyl;R.sup.11 is hydrogen or lower alkyl; andR.sup.12 is hydrogen, lower alkyl, or fluoro lower alkyl;with the proviso that R.sup.8 and R.sup.9 cannot both be hydrogen; and the pharmaceutically acceptable salts thereof.Type: GrantFiled: August 29, 1991Date of Patent: October 5, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Alistair W. Lochead, Michel J. Navet, Peter E. Hicks
-
Patent number: 5250535Abstract: Compounds useful as antiviral agents are defined by the following formula: ##STR1## and the pharmaceutically acceptable acid addition salts thereof wherein R.sup.1 is hydrogen or --C(O)R.sup.7 wherein R.sup.7 is hydrogen, alkyl of one to nineteen carbon atoms, hydroxyalkyl of one to eight carbon atoms, alkoxyalkyl of two to nine carbon atoms, alkenyl of two to nineteen carbon atoms, phenyl, 1-adamantyl or 2-carboxyethyl and the pharmaceutically acceptable alkali metal salts thereof;R.sup.2 is --C(O)R.sup.7 wherein R.sup.7 is as defined above;R.sup.3 is hydrogen, halo, thio, lower alkylthio of one to six carbon atoms, azido, NR.sup.9 R.sup.10 wherein R.sup.9 and R.sup.10 are independently hydrogen or lower alkyl of one to six carbon atoms or --NHC(O)R.sup.8 wherein R.sup.8 is hydrogen, alkyl of one to nineteen carbon atoms or 1-adamantyl; and(a) R.sup.6 is hydrogen, halo, lower alkoxy of one to six carbon atoms, azido, thio, lower alkylthio of one to six carbon atoms, --NR.sup.9 R.sup.10 wherein R.sup.9 and R.Type: GrantFiled: December 22, 1982Date of Patent: October 5, 1993Assignee: Syntex Inc.Inventors: Julien P. H. Verheyden, John C. Martin
-
Patent number: 5248788Abstract: This invention relates to a novel process for making an allenic prostanoic acid derivative in the form of a single stereoisomer, or a mixture of stereoisomers, represented by the formula (I): ##STR1## wherein R is lower alkyl, R.sup.1 is a protecting group which can be selectively removed in the presence of R.sup.2, R.sup.2 is an acid-labile, base-stable protecting group, X is --(CH.sub.2).sub.2 --, trans --CH.dbd.CH-- or --C.tbd.C--, Y is --C(R.sup.3)(OR.sup.2)CH.sub.2 --, in which --OR.sup.2 is in the .alpha. or .beta. configuration and R.sup.3 is hydrogen or methyl, Z is alkyl, or phenyl, benzyl or phenoxy each optionally substituted on the phenyl ring, and the wavy lines represent the .alpha. or .beta. configuration with the proviso that when one wavy line is .alpha. the other is .beta..Type: GrantFiled: January 18, 1990Date of Patent: September 28, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Gary F. Cooper, Colin C. Beard, David Y. Jackson, Douglas L. Wren
-
Patent number: 5247083Abstract: Mycophenolate mofetil is made non-catalytically by refluxing mycophenolic acid with 2-morpholinoethanol in an inert organic solvent capable of azeotropic removal of water.Type: GrantFiled: December 18, 1992Date of Patent: September 21, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Martin Knox, Gregory Donegan, Dennis A. Smith
-
Patent number: 5232707Abstract: There is disclosed a process for the extraction of volatile solvents entrained in a polymer-based pharmaceutical composition designed for sustained release of drug over an extended period of time prepared in microcapsule form wherein the composition comprises at least one hormonally active water-soluble polypeptide in an effective amount greater than a conventional single dose and a biocompatible, bioerodable encapsulating polymer, which process comprises the steps of contacting the composition to a stream of dense gas, that is, pressurized gas and then removing the dense gas, and volatile solvents contained therein, extracted from the pharmaceutical composition.Type: GrantFiled: September 13, 1991Date of Patent: August 3, 1993Assignee: Syntex (U.S.A.) Inc.Inventor: David M. Lokensgard
-
Patent number: 5231181Abstract: The invention provides a process for preparing single enantiomers of compounds represented by the formula: ##STR1## and chiral acid addition salts thereof; wherein: X and Y are independently hydrogen; lower alkyl; lower alkoxy; or halo; or X and Y taken together is methylenedioxy or ethylene-1,2-dioxy;which includes reduction of a compound represented by the formula: ##STR2## to give a mixture of stereoisomers represented by the formula: ##STR3## wherein each wavy line independently represents a bond in either the .alpha. or .beta. position;followed by dissolving the mixture of stereoisomers and a chiral resolving acid in a suitable solvent and allowing the solution to crystallize, giving a salt of the desired enantiomer.Type: GrantFiled: March 21, 1991Date of Patent: July 27, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Norman H. Dyson, John O. Gardner, John C. Rohloff
-
Patent number: 5229387Abstract: Compounds of the formula ##STR1## wherein: m is an integer of 1-6;n is an integer of 1 or 2;X and Y are independently hydrogen; hydroxy; lower alkyl; lower alkoxy; or halo; or X and Y when adjacent and taken together are methylenedioxy or ethylene-1,2-dioxy;R is ##STR2## wherein: R.sup.1 and R.sup.2 are independently hydrogen or lower alkyl, or when taken together with the carbon to which they are attached are cycloalkyl;R.sup.3 is hydrogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl or halo; and ##STR3## and pharmaceutically acceptable acid addition salts thereof. The compounds and salts exhibit useful pharmacological properties, including selective .alpha..sub.2 -adrenoceptor antagonist properties and 5-HT.sub.1A receptor partial agonist properties, and are particularly useful for the treatment of sexual dysfunction, depression and anxiety.Type: GrantFiled: September 20, 1991Date of Patent: July 20, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Robin D. Clark, Brian H. Vickery, Mike Spedding
-
Patent number: 5225590Abstract: Intermediates and methods for producing intermediates for use in preparing 9-(1,3-dihydroxy-2-propoxymethyl)-guanine and esters and ethers thereof.Type: GrantFiled: April 26, 1988Date of Patent: July 6, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: David J. Morgans, Jr., Harlan H. Chapman
-
Patent number: 5212195Abstract: Compound of the Formula (I), (II), or (III): ##STR1## wherein: R.sup.1 is lower alkyl or 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl;R.sup.2 is lower alkyl when R.sup.1 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl; or R.sup.2 is 2"-(1H-tetrazol-5-yl)biphenyl-4'-ylmethyl when R.sup.1 is lower alkyl;R.sup.3 is hydrogen or lower alkyl;X is hydrogen, lower alkyl, halogen, --C(O)CF.sub.3, --CO.sub.2 R.sup.4, or --C(O)NR.sup.5 R.sup.6 ;Y is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, or --CO.sub.2 R.sup.4 ;Z is hydrogen, lower alkyl, lower alkoxy, or halogen; with the proviso that Y and Z cannot be attached to the nitrogen atom in Formula (II); whereinR.sup.4 is hydrogen or lower alkyl;R.sup.5 is hydrogen or lower alkyl;R.sup.6 is hydrogen or lower alkyl; orR.sup.5 and R.sup.6 taken together with the nitrogen to which they are attached represent a heterocycle;and pharmaceutically acceptable salts thereof, exhibit useful pharmacological properties, and are particularly useful as angiotensin II antagonists.Type: GrantFiled: May 13, 1992Date of Patent: May 18, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: Robin D. Clark, David E. Clarke, Lawrence E. Fisher, Alam Jahangir
-
Patent number: 5212288Abstract: In a process for the solid phase synthesis of a polypeptide containing at least one serine residue, the improvement comprising temporarily protecting the side chain of the serine residue with a protecting group which is removed immediately following the addition of the serine to the peptide chain.Type: GrantFiled: February 8, 1991Date of Patent: May 18, 1993Assignee: Syntex (U.S.A.) Inc.Inventors: John J. Nestor, Jr., Natalie L. McClure, Humberto Arzeno